For breast cancer patients, the odds of having NT-proBNP levels above 600 ng/L were lower compared to the reference group ("Other location"), with an estimated log odds of -1.322. This corresponds to an odds ratio of 0.267 (95% CI: 0.0235-3.02), though the difference was not statistically significant (p = 0.286). Here, NPPB is linked to breast cancer.